Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.
Hematologic malignancies are predominantly treated with chemotherapy or a combination of chemotherapy with monoclonal antibodies. Current treatment regimens often are not satisfactory due to severe side effects and a substantial proportion of relapsed patients. This has prompted the development of better tolerated and more efficacious immunotherapeutic strategies for the treatment of lymphoma and leukemia. With blinatumomab (MT103) a first antibody, which can potentially engage all cytotoxic T cells of a patient for tumor cell lysis, is now available for clinical evaluation. Blinatumomab is a single-chain bispecific antibody construct with specificity for CD19 and CD3 belonging to the class of bispecific T cell engager. Here, we review the current progress in development of blinatumomab for treatment of patients with CD19-expressing hematological malignancies.
Nagorsen
Dirk
D
Micromet AG, Germany. dirk.nagorsen@micromet.de
Bargou
Ralf
R
Ruttinger
Dominik
D
Kufer
Peter
P
Baeuerle
Patrick A
PA
Zugmaier
Gerhard
G
D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D018941:Antigens, CD19 / Q000276:immunology; D001402:B-Lymphocytes / Q000166:cytology / Q000276:immunology; D003602:Cytotoxicity, Immunologic / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007938:Leukemia / Q000276:immunology / Q000628:therapy*; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*; D018448:Models, Immunological; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*
D018033:Antibodies, Bispecific; D018941:Antigens, CD19; C510808:blinatumomab